Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

Aino Rajamäki; Kaisa Sunela; Roosa E.I. Prusila; Milla E.L. Kuusisto; Santiago Mercadal; Tuomas Selander; Hanne Kuitunen; Marjukka Pollari; Esa Jantunen; Ilja Nystrand; Juan Manuel Sancho; Marc Sorigue; Outi Kuittinen

doi:10.1080/10428194.2021.1872073

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

Aino Rajamäki^*
, Kaisa Sunela
, Roosa E.I. Prusila
, Milla E.L. Kuusisto
, Santiago Mercadal
, Tuomas Selander
, Hanne Kuitunen
, Marjukka Pollari
, Esa Jantunen
, Ilja Nystrand
, Juan Manuel Sancho
, Marc Sorigue
, Outi Kuittinen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

6 Citations (Scopus)

19 Downloads (Pure)

Abstract

Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of disease (POD) remains unclear. We collected real-life data from nine hospitals in Finland and Spain including 1020 FL patients to study the influence of sex on disease outcome. The median follow-up duration was 67 months (range 0–226 months). Female patients showed better progression-free survival (PFS) (hazard ratio [HR], 0.720; 95% confidence interval [CI], 0.588–0.881), disease-specific survival (DSS) (HR, 0.653; 95% CI, 0.448–0.951), and overall survival (OS) (HR, 0.653; 95% CI, 0.501–0.853) than male patients. However, there were no significant sex differences in prognosis in patients with early POD. This study strengthens the understanding that male sex is an adverse prognostic factor for FL. However, this difference does not apply to patients with early POD.

Original language	English
Journal	Leukemia and Lymphoma
Volume	62
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2021.1872073
Publication status	Published - 2021
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Follicular lymphoma
POD24
prognosis
sex

Publication forum classification

Publication forum level 1

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2021.1872073Licence: CC BY-NC-ND

10428194.2021.1872073Final published version, 2.07 MBLicence: CC BY-NC-ND

http://urn.fi/URN:NBN:fi:tuni-202105215258Licence: CC BY-NC-ND

Cite this

Rajamäki, A., Sunela, K., Prusila, R. E. I., Kuusisto, M. E. L., Mercadal, S., Selander, T., Kuitunen, H., Pollari, M., Jantunen, E., Nystrand, I., Sancho, J. M., Sorigue, M., & Kuittinen, O. (2021). Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months. Leukemia and Lymphoma, 62(7). https://doi.org/10.1080/10428194.2021.1872073

@article{97d24143d3b544fc9346a7e05a908c77,

title = "Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months",

abstract = "Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of disease (POD) remains unclear. We collected real-life data from nine hospitals in Finland and Spain including 1020 FL patients to study the influence of sex on disease outcome. The median follow-up duration was 67 months (range 0{\textendash}226 months). Female patients showed better progression-free survival (PFS) (hazard ratio [HR], 0.720; 95\% confidence interval [CI], 0.588{\textendash}0.881), disease-specific survival (DSS) (HR, 0.653; 95\% CI, 0.448{\textendash}0.951), and overall survival (OS) (HR, 0.653; 95\% CI, 0.501{\textendash}0.853) than male patients. However, there were no significant sex differences in prognosis in patients with early POD. This study strengthens the understanding that male sex is an adverse prognostic factor for FL. However, this difference does not apply to patients with early POD.",

keywords = "Follicular lymphoma, POD24, prognosis, sex",

author = "Aino Rajam{\"a}ki and Kaisa Sunela and Prusila, \{Roosa E.I.\} and Kuusisto, \{Milla E.L.\} and Santiago Mercadal and Tuomas Selander and Hanne Kuitunen and Marjukka Pollari and Esa Jantunen and Ilja Nystrand and Sancho, \{Juan Manuel\} and Marc Sorigue and Outi Kuittinen",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.",

year = "2021",

doi = "10.1080/10428194.2021.1872073",

language = "English",

volume = "62",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "American School of Classical Studies at Athens",

number = "7",

}

TY - JOUR

T1 - Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

AU - Rajamäki, Aino

AU - Sunela, Kaisa

AU - Prusila, Roosa E.I.

AU - Kuusisto, Milla E.L.

AU - Mercadal, Santiago

AU - Selander, Tuomas

AU - Kuitunen, Hanne

AU - Pollari, Marjukka

AU - Jantunen, Esa

AU - Nystrand, Ilja

AU - Sancho, Juan Manuel

AU - Sorigue, Marc

AU - Kuittinen, Outi

PY - 2021

Y1 - 2021

N2 - Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of disease (POD) remains unclear. We collected real-life data from nine hospitals in Finland and Spain including 1020 FL patients to study the influence of sex on disease outcome. The median follow-up duration was 67 months (range 0–226 months). Female patients showed better progression-free survival (PFS) (hazard ratio [HR], 0.720; 95% confidence interval [CI], 0.588–0.881), disease-specific survival (DSS) (HR, 0.653; 95% CI, 0.448–0.951), and overall survival (OS) (HR, 0.653; 95% CI, 0.501–0.853) than male patients. However, there were no significant sex differences in prognosis in patients with early POD. This study strengthens the understanding that male sex is an adverse prognostic factor for FL. However, this difference does not apply to patients with early POD.

AB - Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of disease (POD) remains unclear. We collected real-life data from nine hospitals in Finland and Spain including 1020 FL patients to study the influence of sex on disease outcome. The median follow-up duration was 67 months (range 0–226 months). Female patients showed better progression-free survival (PFS) (hazard ratio [HR], 0.720; 95% confidence interval [CI], 0.588–0.881), disease-specific survival (DSS) (HR, 0.653; 95% CI, 0.448–0.951), and overall survival (OS) (HR, 0.653; 95% CI, 0.501–0.853) than male patients. However, there were no significant sex differences in prognosis in patients with early POD. This study strengthens the understanding that male sex is an adverse prognostic factor for FL. However, this difference does not apply to patients with early POD.

KW - Follicular lymphoma

KW - POD24

KW - prognosis

KW - sex

U2 - 10.1080/10428194.2021.1872073

DO - 10.1080/10428194.2021.1872073

M3 - Article

AN - SCOPUS:85100762740

SN - 1042-8194

VL - 62

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

Abstract

UN SDGs

Keywords

Publication forum classification

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this